WP
LXRX icon

Woodline Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Woodline Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-229,376
Closed -$169K – 980
2024
Q4 		$169K Sell
229,376
-982,548
-81% -$1.18M ﹤0.01% 910
2024
Q3 		$1.9M Buy
+1,211,924
New +$2.16M 0.02% 480

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners's LXRX Position: Q1 2025 in Review

Woodline Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 229,376 shares — an estimated $169K sold.

Woodline Partners first reported a position in LXRX in Q3 2024 and held it in 2 quarters. The position peaked at $1.9M in Q3 2024. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.

  • Woodline Partners reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Woodline Partners sold 229,376 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $169K.
  • Woodline Partners first reported a position in Lexicon Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Woodline Partners's Lexicon Pharmaceuticals position peaked at $1.9M in Q3 2024.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.